A tiny Long Island biotechnology startup in a global race to develop a COVID-19 vaccine has rolled out plans for a human trial.
The Phase 1 trial using about 50 paid young adult volunteers will evaluate the safety of the Codagenix Inc. vaccine and will be conducted in London by a unit of Dublin-based Open Orphan plc.
Codagenix Inc.’s vaccine is made from a live, but attenuated — or weakened — version of the whole virus that is re-engineered to slow its ability to make copies of itself.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).